BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection
June 29, 2021 13:58 ET | BioAegis Therapeutics
NORTH BRUNSWICK, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
Rancho Santa Fe Bio.png
Rancho Santa Fe Bio, Inc. Enters into Worldwide Exclusive License Agreement with Sanofi for Ataciguat
June 17, 2021 05:00 ET | Rancho Santa Fe Bio
SAN DIEGO and PARIS, June 17, 2021 (GLOBE NEWSWIRE) -- Rancho Santa Fe Bio, Inc. (“RSF Bio” or the “Company”), a San Diego, California-based clinical-stage cardiovascular platform company, today...
Adamis Pharmaceuticals logo
Adamis Highlights National Institute of Health Study Identifying Tempol as a Potential Antiviral Drug for COVID-19
June 07, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
NIH Researchers Contend “Tempol may be a Promising Oral Antiviral Treatment for COVID-19” Research Team Intends to Conduct Additional Studies, Including a Prospective Clinical Study for Tempol in the...
Concentric Methods Wins High Recognition from KellyOCG
June 02, 2021 10:20 ET | Cape Fox FCG
Manassas, VA, June 02, 2021 (GLOBE NEWSWIRE) -- On May 25, 2021, Concentric Methods, LLC, a Cape Fox Corporation (CFC) subsidiary, was one of 23 suppliers recently recognized at a virtual ceremony...
AvantGen's logo-final.JPG
AvantGen receives an award from the NIH/RADx to commercialize its anti-SARS-CoV-2 nucleocapsid antibodies for ultra-high sensitivity lateral flow assay development
May 25, 2021 06:00 ET | AvantGen Inc
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- AvantGen, a San Diego-based biotech, is a leader in the use of yeast display technology for human and rabbit monoclonal antibody discovery and...
TrevenaLogo.jpg
Trevena Announces TRV027 Selected by NIH-Funded ACTIV Initiative For COVID-19 Trial
May 06, 2021 07:03 ET | Trevena Inc.
-- Vanderbilt University Medical Center (VUMC) is coordinating multiple-arm, multi-site ACTIV-4d study targeting RAAS TRV027 to be dosed in ~300 COVID-19 patients -- CHESTERBROOK, Pa., May 06,...
TrevenaLogo.jpg
Trevena Reports First Quarter 2021 Results
May 06, 2021 07:00 ET | Trevena Inc.
-- Company reaffirms YE target of 100 formulary approvals for OLINVYK® Announces new OLINVYK clinical outcomes study to further examine potential benefit on respiratory, GI, and...
TrevenaLogo.jpg
Trevena, Inc. Reports Fourth Quarter and Full Year 2020 Results
March 09, 2021 07:00 ET | Trevena Inc.
-- OLINVYK™ approved in U.S.; customer-facing teams now fully deployed Primary study completion for TRV027 in COVID-19 patients expected in 1H 2021 IND for TRV045 (S1P1 receptor modulator) on track...
VIR_logo_large.jpg
Vir Biotechnology and GSK Provide Update on NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
March 03, 2021 09:00 ET | Vir Biotechnology, Inc.
SAN FRANCISCO and LONDON, March 03, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today provided an update on the VIR-7831 (GSK4182136) arm...
images.jpg
Connectyx Announces Grant of Exclusive Worldwide License from National Institutes of Health for Repurposing Metformin to Treat Degenerative Eye Disease
February 04, 2021 11:17 ET | Connectyx Technologies Holdings Group, Inc
Boca Raton, FL, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel...